Please login to the form below

Not currently logged in
Email:
Password:

New appointment at Synexus

Synexus has appointed Jeremy Hickling as senior vice president of portfolio management

Synexus has appointed Jeremy Hickling as senior vice president of portfolio management. Jeremy has 11 years' industry experience and brings significant, senior level knowledge to his new role.

Michael Fort, Synexus' chief executive, said: "We had a very successful and exciting 2009, culminating in our acquisition of ClinPharm in Germany. With Jeremy on board, it is important that we continue to expand our business development by demonstrating to a wider audience how we can help pharma, biotechs and CROs reduce costs and speed up clinical trials."

Jeremy, was previously a senior director within the late phase PACE group for leading contract research organisation PAREXEL where he was responsible for key projects and relationship management, study design and strategy. Prior to this he worked as the head of UK planning and operations for Biogen Idec Inc.

Jeremy said: "I've been very fortunate to work for some of the best organisations in the pharma industry. The opportunity to work with Synexus gives me the chance to be involved with a company that is not only growing rapidly, but is also making real changes to the clinical trials industry. I am keen to be a part of that and to demonstrate the real benefits the Synexus model offers to pharma and CRO clients alike."

Synexus is based outside Manchester and is the world's largest multinational organisation specialising in the recruitment of patients and the running of trials at its own dedicated research centres.

19th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics